Browse EV MemProt Atlas
Supporting publications (n)
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| PCDAB | Q9Y5I1 | Protocadherin alpha-11 (PCDH-alpha-11) | 1 | Adhesion and uptake mediation | 1 | 0.25 | ||||
| PCDH1 | Q08174 | Protocadherin-1 (Cadherin-like protein 1) (Protocadherin-42) (PC42) | Plasma proteinsPredicted intracellular proteinsPredicted membrane proteins | 1 | Adhesion and uptake mediation | 1 | 0.25 | |||
| PCDH9 | Q9HC56 | Protocadherin-9 | 1 | Adhesion and uptake mediation | 1 | 0.25 | ||||
| PDCD1 | Q15116 | Programmed cell death protein 1 (Protein PD-1) (hPD-1) (CD antigen CD279) | CD markersDisease related genesFDA approved drug targets | 1 | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 1 | 0.25 | |||
| PE2R3 | P43115 | Prostaglandin E2 receptor EP3 subtype (PGE receptor EP3 subtype) (PGE2 receptor EP3 subtype) (PGE2-R) (Prostanoid EP3 receptor) | FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins | 7 | AsthmaChronic arterial occlusive diseaseGlaucoma | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 1 | 0.25 | ||
| PGFRB | P09619 | Platelet-derived growth factor receptor beta (PDGF-R-beta) (PDGFR-beta) (EC 2.7.10.1) (Beta platelet-derived growth factor receptor) (Beta-type platelet-derived growth factor receptor) (CD140 antigen-like family member B) (Platelet-derived growth factor receptor 1) (PDGFR-1) (CD antigen CD140b) | Cancer-related genesCD markersDisease related genes | 1 | Acute diabete complicationAlzheimer diseaseGram-positive bacterial infection | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 1 | 0.25 | ||
| PI2R | P43119 | Prostacyclin receptor (Prostaglandin I2 receptor) (PGI receptor) (PGI2 receptor) (Prostanoid IP receptor) | 7 | AbortionArterial occlusive diseaseAsthma | Clinical-translation mediationImmune mediationReceptor-signaling mediation | 1 | 0.25 | |||
| PLXA1 | Q9UIW2 | Plexin-A1 (Semaphorin receptor NOV) | Disease related genesPredicted intracellular proteinsPredicted membrane proteins | 1 | Adhesion and uptake mediationImmune mediationReceptor-signaling mediation | 1 | 0.25 | |||
| PLXA2 | O75051 | Plexin-A2 (Semaphorin receptor OCT) | Predicted membrane proteins | 1 | Adhesion and uptake mediationReceptor-signaling mediation | 1 | 0.25 | |||
| PLXB2 | O15031 | Plexin-B2 (MM1) | Plasma proteinsPredicted intracellular proteinsPredicted membrane proteins | 1 | Adhesion and uptake mediationReceptor-signaling mediation | 1 | 0.25 | |||
| PLXB3 | Q9ULL4 | Plexin-B3 | Plasma proteinsPredicted intracellular proteinsPredicted membrane proteins | 1 | Adhesion and uptake mediationImmune mediationReceptor-signaling mediation | 1 | 0.25 | |||
| PLXD1 | Q9Y4D7 | Plexin-D1 | Plasma proteinsPredicted intracellular proteinsPredicted membrane proteins | 1 | Adhesion and uptake mediationReceptor-signaling mediation | 1 | 0.25 | |||
| PTC1 | Q13635 | Protein patched homolog 1 (PTC) (PTC1) | Cancer-related genesDisease related genesHuman disease related genes | 12 | Fusion and delivery mediationMetabolism mediationReceptor-signaling mediation | 1 | 0.25 | |||
| PTPRA | P18433 | Receptor-type tyrosine-protein phosphatase alpha (Protein-tyrosine phosphatase alpha) (R-PTP-alpha) (EC 3.1.3.48) | EnzymesPlasma proteinsPredicted intracellular proteins | 1 | Adhesion and uptake mediationMetabolism mediationReceptor-signaling mediation | 1 | 0.25 | |||
| PTPRC | P08575 | Receptor-type tyrosine-protein phosphatase C (EC 3.1.3.48) (Leukocyte common antigen) (L-CA) (T200) (CD antigen CD45) | Cancer-related genesCD markersDisease related genes | 1 | Acute myeloid leukaemiaDiffuse large B-cell lymphomaLeukaemia | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 1 | 0.25 | ||
| PTPRJ | Q12913 | Receptor-type tyrosine-protein phosphatase eta (Protein-tyrosine phosphatase eta) (R-PTP-eta) (EC 3.1.3.48) (Density-enhanced phosphatase 1) (DEP-1) (HPTP eta) (Protein-tyrosine phosphatase receptor type J) (R-PTP-J) (CD antigen CD148) | CD markersEnzymesPlasma proteins | 1 | Adhesion and uptake mediationFusion and delivery mediationImmune mediation | 1 | 0.25 | |||
| PTPRQ | Q9UMZ3 | Phosphatidylinositol phosphatase PTPRQ (EC 3.1.3.67) (EC 3.1.3.86) (EC 3.1.3.95) (Receptor-type tyrosine-protein phosphatase Q) (PTP-RQ) (R-PTP-Q) | Human disease related genesMetabolic proteinsPredicted intracellular proteins | 1 | Fusion and delivery mediationMetabolism mediation | 1 | 0.25 | |||
| PTPRZ | P23471 | Receptor-type tyrosine-protein phosphatase zeta (R-PTP-zeta) (EC 3.1.3.48) (Protein-tyrosine phosphatase receptor type Z polypeptide 1) (Protein-tyrosine phosphatase receptor type Z polypeptide 2) (R-PTP-zeta-2) | EnzymesPlasma proteinsPredicted membrane proteins | 1 | Clinical-translation mediationImmune mediationMetabolism mediation | 1 | 0.25 | |||
| S12A5 | Q9H2X9 | Solute carrier family 12 member 5 (Electroneutral potassium-chloride cotransporter 2) (K-Cl cotransporter 2) (hKCC2) (Neuronal K-Cl cotransporter) | Disease related genesFDA approved drug targetsHuman disease related genes | 12 | Epilepsy/seizure | Clinical-translation mediationFusion and delivery mediation | 1 | 0.25 | ||
| S12A7 | Q9Y666 | Solute carrier family 12 member 7 (Electroneutral potassium-chloride cotransporter 4) (K-Cl cotransporter 4) | Metabolic proteinsPlasma proteinsPredicted membrane proteins | 12 | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 1 | 0.25 | |||
| S1PR1 | P21453 | Sphingosine 1-phosphate receptor 1 (S1P receptor 1) (S1P1) (Endothelial differentiation G-protein coupled receptor 1) (Sphingosine 1-phosphate receptor Edg-1) (S1P receptor Edg-1) (CD antigen CD363) | Cancer-related genesCD markersFDA approved drug targets | 7 | Acne vulgarisCardiovascular diseaseCrohn disease | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.25 | ||
| S1PR4 | O95977 | Sphingosine 1-phosphate receptor 4 (S1P receptor 4) (S1P4) (Endothelial differentiation G-protein coupled receptor 6) (Sphingosine 1-phosphate receptor Edg-6) (S1P receptor Edg-6) | 7 | Receptor-signaling mediation | 1 | 0.25 | ||||
| S1PR5 | Q9H228 | Sphingosine 1-phosphate receptor 5 (S1P receptor 5) (S1P5) (Endothelial differentiation G-protein-coupled receptor 8) (Sphingosine 1-phosphate receptor Edg-8) (S1P receptor Edg-8) | FDA approved drug targetsG-protein coupled receptorsPredicted intracellular proteins | 7 | Multiple sclerosis | Clinical-translation mediationReceptor-signaling mediation | 1 | 0.25 | ||
| S22A4 | Q9H015 | Solute carrier family 22 member 4 (Ergothioneine transporter) (ET transporter) (ETTh) (Organic cation/carnitine transporter 1) (OCTN1) | Disease related genesHuman disease related genesMetabolic proteins | 12 | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 1 | 0.25 | |||
| S23A2 | Q9UGH3 | Solute carrier family 23 member 2 (Na(+)/L-ascorbic acid transporter 2) (Nucleobase transporter-like 1 protein) (Sodium-dependent vitamin C transporter 2) (hSVCT2) (Yolk sac permease-like molecule 2) | Metabolic proteinsPredicted membrane proteinsTransporters | 12 | Autoimmune liver diseaseUrinary tract infectionVitamin deficiency | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 1 | 0.25 |